{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:42:02Z","timestamp":1791052922455,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-146827OB-I00"],"award-info":[{"award-number":["PID2023-146827OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RYC2020-029098-I"],"award-info":[{"award-number":["RYC2020-029098-I"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019364","name":"Revolution Medicines","doi-asserted-by":"publisher","award":["MICIU\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MICIU\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/100019364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023561","name":"Government of Spain Ministry of Universities","doi-asserted-by":"publisher","award":["PID2023-152755OB-I00"],"award-info":[{"award-number":["PID2023-152755OB-I00"]}],"id":[{"id":"10.13039\/501100023561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ccell.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:42:00Z","timestamp":1776955320000},"page":"1218-1234.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Rodrigo","family":"Entrialgo-Cadierno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Morali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ya\u00f1ez-Bartolome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Macaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cueto-Ure\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sin-Coscujuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Senent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Raghulan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Ponz-Sarvise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximo","family":"Pechuan-Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Guruceaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Schumpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia V.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin O.","family":"Herzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian V.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Aronchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silve","family":"Vicent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.03.020_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib2","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.03.020_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.03.020_bib5","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.03.020_bib6","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS G12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.03.020_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.03.020_bib8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to krasg12c inhibition through a novel kras switch-ii pocket mutation and polyclonal alterations converging on ras\u2013mapk reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.03.020_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.03.020_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ccell.2026.03.020_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2026.03.020_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma-evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ccell.2026.03.020_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.03.020_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.03.020_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.03.020_bib19","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.03.020_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ccell.2026.03.020_bib22","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.03.020_bib23","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.03.020_bib24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib25","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2026.03.020_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib27","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS Variant Subtypes with Survival and Recurrence in Patients with Surgically Treated Intrahepatic Cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ccell.2026.03.020_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS Allelic Variants in Biliary Tract Cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ccell.2026.03.020_bib31","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.humpath.2013.07.026","article-title":"The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome","volume":"44","author":"Robertson","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ccell.2026.03.020_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2026.03.020_bib33","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2026.03.020_bib34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ccell.2026.03.020_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121868","article-title":"Genetic mouse models as in vivo tools for cholangiocarcinoma research","volume":"11","author":"Erice","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ccell.2026.03.020_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","article-title":"Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance","volume":"20","author":"Calvisi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2026.03.020_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2021.03.028","article-title":"FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted","volume":"75","author":"Vallejo","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ccell.2026.03.020_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-9420-5_16","article-title":"3,5-diethoxycarbonyl-1,4-dihydrocollidine diet: A rodent model in cholestasis research","volume":"1981","author":"Pose","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ccell.2026.03.020_bib39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/2159-8290.CD-12-0446","article-title":"Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS -mutant lung cancer","volume":"3","author":"Molina-Arcas","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib40","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","article-title":"Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer","volume":"14","author":"Araujo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164413","article-title":"Kras oncogene ablation prevents resistance in advanced lung adenocarcinoma","volume":"133","author":"Salm\u00f3n","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ccell.2026.03.020_bib42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ccell.2026.03.020_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.03.020_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14294","article-title":"An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer","volume":"8","author":"Vallejo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.03.020_bib46","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C\u2013Mutant Non\u2013Small Cell Lung Cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2026.03.020_bib48","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.03.020_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.03.020_bib51","doi-asserted-by":"crossref","first-page":"LB281","DOI":"10.1158\/1538-7445.AM2025-LB281","article-title":"Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies","volume":"85","author":"Kar","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2026.03.020_bib53","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","article-title":"T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma","volume":"15","author":"Orlen","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.020_bib54","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/bjc.2015.337","article-title":"Major histocompatibility complex class i expression impacts on patient survival and type and density of immune cells in biliary tract cancer","volume":"113","author":"Goeppert","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2026.03.020_bib55","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/labinvest.3780187","article-title":"Modified culture conditions enhance expression of differentiated phenotypic properties of normal rat cholangiocytes","volume":"80","author":"Salter","year":"2000","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ccell.2026.03.020_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12943-023-01788-w","article-title":"The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer","volume":"22","author":"Entrialgo-Cadierno","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ccell.2026.03.020_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41828-z","article-title":"Signature-driven repurposing of Midostaurin for combination with MEK1\/2 and KRASG12C inhibitors in lung cancer","volume":"14","author":"Macaya","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.03.020_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: A Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2026.03.020_bib59","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib60","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2026.03.020_bib61","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2026.03.020_bib62","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: A flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2026.03.020_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2026.03.020_bib64","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From fastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr. Protoc. Bioinforma"},{"key":"10.1016\/j.ccell.2026.03.020_bib65","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib66","series-title":"R: A Language and Environment for Statistical Computing","year":"2019"},{"key":"10.1016\/j.ccell.2026.03.020_bib67","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/nar\/gks003","article-title":"Cn.MOPS: Mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate","volume":"40","author":"Klambauer","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2026.03.020_bib68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/bioinformatics\/btl646","article-title":"A faster circular binary segmentation algorithm for the analysis of array CGH data","volume":"23","author":"Venkatraman","year":"2007","journal-title":"Bioinformatics"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:25:31Z","timestamp":1783185931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826001741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1535610826001741"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.03.020","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}